Pharmaceutical regulation
Pharmaceutical R&D
Pharmacare
Frontier injustice: the American threat to Canada’s drug supply
Adam R. Houston & Amir Attaran. Canadian Journal of Public Health. 2019. (OPEN ACCESS)
Could the Paragraph 6 Compulsory License System be revised to increase participation by the generics industry? Lessons learned from an unheralded and unsuccessful attempt to use Canada’s Access to Medicines Regime
Adam R. Houston & Reed Beall. McGill Journal of Law and Health. 2019. (OPEN ACCESS)
Reforming Canada’s Special Access Programme to Improve Access to Off-Patent Essential Medicines
Adam R. Houston (co-author). JAMMI. 2018. (OPEN ACCESS)
Universal pharmacare and federalism: Policy options for Canada
Colleen M. Flood, Bryan Thomas, Asad Ali Moten, Patrick Fafard. IRPP. 2018. (OPEN ACCESS)
There’s a Drug to Treat COVID-19, but Canada Must Act Soon to Ensure Access: Why compulsory licensing is the right tool for right now
Adam Houston. The Tyee. July 2020.
New Tricks for Old Drugs? Canada must change how it accesses Essential Medicines
Adam Houston. healthydebate.ca. June 2020.
Pharmaceutical Policy Excludes the Most Vulnerable
Adam R. Houston, Ryan Cooper, Richard Long. IRPP. Jan 2020.
Pharmacare: The Promise and Perils
w/ Colleen Flood. CBC Radio. Nov 2019.
Five decades in the making, our national pharmacare still has a long way to go
Colleen M. Flood. Globe and Mail. June 2019.
Proposed pharmacare plan is a different beast from medicare
Colleen M. Flood. Policy Options. June 2019.
Provinces must act to stop Big Pharma from hurting Canadians
Vanessa Gruben, Louise Bélanger-Hardy. Toronto Star. Aug 2017.
Israel's Successful Strategies for Controlling Pharmaceutical Costs – Relevance to Canada?
Bruce Rosen, Matthew Grougham. May 2017.
How Pharmaceutical Regulation Facilitated Industry’s Knowledge Control and Fraud. And Whether It Can Still Save Us.
Trudo Lemmens. Oct 2015.
Réglementation pharmaceutique
R&D pharmaceutique
Pharmacare
Frontier injustice: the American threat to Canada’s drug supply
Adam R. Houston & Amir Attaran. Canadian Journal of Public Health. 2019. (OPEN ACCESS)
Could the Paragraph 6 Compulsory License System be revised to increase participation by the generics industry? Lessons learned from an unheralded and unsuccessful attempt to use Canada’s Access to Medicines Regime
Adam R. Houston & Reed Beall. McGill Journal of Law and Health. 2019. (OPEN ACCESS)
Reforming Canada’s Special Access Programme to Improve Access to Off-Patent Essential Medicines
Adam R. Houston (co-author). JAMMI. 2018. (OPEN ACCESS)
Universal pharmacare and federalism: Policy options for Canada
Colleen M. Flood, Bryan Thomas, Asad Ali Moten, Patrick Fafard. IRPP. 2018. (OPEN ACCESS)
There’s a Drug to Treat COVID-19, but Canada Must Act Soon to Ensure Access: Why compulsory licensing is the right tool for right now
Adam Houston. The Tyee. July 2020.
New Tricks for Old Drugs? Canada must change how it accesses Essential Medicines
Adam Houston. healthydebate.ca. June 2020.
Pharmaceutical Policy Excludes the Most Vulnerable
Adam R. Houston, Ryan Cooper, Richard Long. IRPP. Jan 2020.
Pharmacare: The Promise and Perils
w/ Colleen Flood. CBC Radio. Nov 2019.
Five decades in the making, our national pharmacare still has a long way to go
Colleen M. Flood. Globe and Mail. June 2019.
Proposed pharmacare plan is a different beast from medicare
Colleen M. Flood. Policy Options. June 2019.
Provinces must act to stop Big Pharma from hurting Canadians
Vanessa Gruben, Louise Bélanger-Hardy. Toronto Star. Aug 2017.
Israel's Successful Strategies for Controlling Pharmaceutical Costs – Relevance to Canada?
Bruce Rosen, Matthew Grougham. May 2017.
How Pharmaceutical Regulation Facilitated Industry’s Knowledge Control and Fraud. And Whether It Can Still Save Us.
Trudo Lemmens. Oct 2015.